Fusion inhibitors

IDrugs

Volumn 5, Issue 1, 2002, Pages 77-83

  Petrik, Juraj ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 5 HELIX PROTEIN; ANTIVIRUS AGENT; BISPECIFIC CHIMERIC PROTEIN; CD4 IMMUNOGLOBULIN G2; CELL PROTEIN; CL 387626; CTC 96; DOXOVIR; DP 107; ENFUVIRTIDE; FP 21399; GLYCOSPHINGOLIPID INHIBITOR; INTERFERON; ORAGEN; ORAGEN CONJUGATE 33; PRO 140; PROTEINASE INHIBITOR; RFI 641; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; T 391; T 400; T 649; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS FUSION PROTEIN; VIRUS FUSION PROTEIN INHIBITOR; VIRUS FUSION PROTEIN TYPE 1; VIRUS FUSION PROTEIN TYPE 2; VIRUS MEMBRANE PROTEIN; VIRUS PROTEIN; VIRUS RECEPTOR; VP 14637;

CELL MEMBRANE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HEPATITIS C; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE; NONHUMAN; PROTEIN PROTEIN INTERACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SKIN MANIFESTATION; VIRION; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0042896004     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Overbaugh J, Miller AD, Eiden MV: Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev (2001) 65:371-389. Detailed analysis of the complex world of retroviral receptors and co-reptors.
2. Speck P, Haan KM, Longnecker R: Epstein-Barr virus entry into cells. Virology (2000) 277:1-5.
3. Spear PG, Eisenberg RJ, Cohen GH: Three classes of cell surface receptors for α-herpes virus entry. Virology (2000) 275:1-8.
4. Rossmann MG, Bella J, Kolatkar PR, He Y, Wimmer E, Kuhn RJ, Baker TS: Cell recognition and entry by rhino- and enteroviruses. Virology (2000) 269:239-247.
5. Heinz FX, Allison SL: The machinery for flavivirus fusion with host cell membranes. Curr Opin Microbiol (2001) 4:450-455. Review highlighting specific features of class II viral fusion protein (influenza hemagglutinin) and type II fusion
6. Gaudin Y: Reversibility in fusion protein conformational changes. The intriguing case of rhabdovirus-induced membrane fusion. Subcell Biochem (2000) 34:379-408.
7. Skehel JJ, Wiley DC: Coiled coils in both intracellular vesicle and viral membrane fusion. Cell (1998) 95:871-874.
8. Skehel JJ, Cross K, Steinhauer D, Wiley DC: Influenza fusion peptides. Biochem Soc Trans (2001) 29(4):623-626.
9. Schwartz JA, Lium EK, Silverstein SJ: Herpes simplex virus type 1 entry is inhibited by the cobalt chelate complex CTC-96. J Virol (2001) 75:4117-128.
10. Razinkov V, Gazumyan A, Nikitenko A, Ellestad G, Krishnamurthy G: RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol (2001) 8:645-659.
11. Genois N, Barbeau B, Olivier M, Tremblay MJ: Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle. Clin Exp Immunol (2001) 124:32-42.
12. Kliger Y, Shai Y: Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol (2000) 295:163-168. A fine dissection of the HIV-1 fusion process using circular dichroism spectroscopy.
13. Kliger Y, Gallo SA, Peisajovich SG, Munoz-Barroso I, Avkin S, Blumenthal R, Shai Y: Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem (2001) 276:1391-1397.
14. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, Shaw GM, Hunter E: Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol (2001) 75:8605-8614.
15. Rimsky LT, Shugars DC, Matthews TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 72:986-993.
16. Zollner B, Feucht HH, Schroter M, Schafer P, Plettenberg A, Stoehr A, Laufs R: Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS (2001) 15:935-936.
17. Root MJ, Kay MS, Kim PS: Protein design of an HIV-1 entry inhibitor. Science (2001) 291(5505):884-888. Paper describing a clever design of a gp41-derived inhibitor based on a presumption of reciprocal action of HR1 and HR2-derived peptides.
18. Cohen C, Dusek A, Johns E, Green J, Recny M: Patient satisfaction and activities of daily living (ADL) in HIV infected adults using T-20 given by subcutaneous injection (SC) over 48 weeks. Int Aids Soc Conf HIV Pathogenesis Treat (2001) 1 (Buenos Aires).
19. Lalezari J, Drucker J, Demasi R, Hopkin S, and Salgo M: A controlled phase II trial assessing three doses of T-20 in combination with abacavir, amprenavir, low dose ritonavir and efavirenz in non-nucleoside naïve protease inhibitor experienced HIV-1 infected adults. Int Conf Retroviruses Opportunistic Infect (2001) 8 (Chicago): LB5.
20. Church J, Cunningham C, Palumbo P, Sista P, and the P1005 Team: Safety and antiviral activity of chronic subcutaneous administration of T-20 in HIV-1-infected children. Int Conf Retroviruses Opportunistic Infect (2001) 8 (Chicago): 681.
21. Lambert DM, Mathews TJ, Hopkins S, Bolognesi DB: Inhibitors of viral mediated fusion. Int Symp Med Chem (2000) 16 (Bologna): ML31.
22. Bolognesi D, Matthews T, Hopkins S, Kang MC: Development of T-20: The first membrane fusion inhibitor. ACS (2001) 221 (San Diego):MEDI 25.
23. Dezube BJ, Dahl TA, Wong TK, Chapman B, Ono M, Yamaguchi N, Gillies SD, Chen LB, Crumpacker CS: A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: A phase 1 study. J Infect Dis (2000) 182:607-610.
24. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr (2000) 25:99-102. Important synergistic effect between the two types of antiviral compounds.
25. Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, Egbertson M, Melamed JY, Young S, Hamill T, Cole JL, Hazuda DJ: HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA (2000) 97:11244-11249.
26. Vandegraaff N, Kumar R, Hocking H, Burke TR Jr, Mills J, Rhodes D, Burrell CJ, Li P: Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: Putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother (2001) 45:2510-2516.
27. Wyde PR, Moore-Poveda DK, O'Hara B, Ding WD, Mitsner B, Gilbert BE: CL-387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res (1998) 38:31-42.
28. DeClercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, DeVreese K, Debyser Z, Rosenwirth B, Peichl P, Datema R, Thornton D: Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother (1994) 38:668-674.
29. Pevear DC, Tull TM, Direnzo R, Nitz TJ, Collett MS: VP-14637: A subnanomolar inhibitor of respiratory syncytial virus. International Conference on Antiviral Research (2000) 13(Baltimore): Abs 57.
30. Tanox Inc: Tanox to initiate phase I clinical trial of TNX-355 for HIV infection. Press Release (2001) August 01.
31. Columbia University (Silverstein SJ, Lium E, Schwartz J:) Use of cobalt chelates for treating or preventing virus infection. WO-00105396 (2001).
32. Hemisphernx Biopharma Inc: Oragen conjugate 33. US Apl 09/445,559 (2001).
33. US Department of Health & Human Services (Blumenthal R, Puri A, Hug P:) Identification of glycosphingolipids that promote HIV-1 entry into cells and therapeutic applications. WO-00029556 (2000).
34. City of Hope (Rossi JJ, Cagnon L): Ribozymes capable of inhibiting the expression of the CCR5 receptor and uses in preventing HIV-1 infection. WO-09946372 (1999). A highly promising approach for the specific target mRNA depletion.
35. Whitehead Institute for Biomedical Research (Root MJ, Kay MS, Chan DC, Kim PS:) Five-Helix protein useful for inhibiting HIV infection. WO-00144286 (2001).
36. Progenics Pharmaceuticals Inc (Olson WC, Maddon PJ): Novel admixtures of inhibition of HIV-1 infection. WO-00155439 (2001).
37. Trimeris Inc (Barney S, Guthrie KI, Merutka G, Anwer MK, Lambert DM:) Hybrid polypeptides with improved pharmacokinetic properties which are active against HIV and other viral infections. WO-00103723 (2001). Method for enhancing antiviral activity of peptides such as T-20 by constructing hybrid polypeptides consisting of gp41-derived enhancer peptide and a core polypeptide.
38. Petrik J: Recombinant therapeutic fusion proteins. WO-00132893 (2001). Novel concept of antiviral immunotherapy against genetically variable viruses.
39. Thomas Jefferson University (Huang Z): Novel vMIP-II peptide antagonists of CXCR4. WO-00156591 (2001).
40. University of Maryland Biotechnology Institute (Devico AI, Fouts TR, Tuskan RG:) Virus coat protein/receptor chimeras and methods of use. WO-00127294 (2001).
41. Chiron SPA (Abrignani S:) Binding protein for hepatitis C virus. WO-09709349 (1997).
42. Trimeris Inc (Johnson RM, Lambert DM:) Methods of treating HIV infection using a combination of a viral fusion inhibitor and an antiviral agent. WO-09640191 (1996). Beneficial, pontentially synergistic effect of the two classes of compounds.
43. US Department of Health & Human Services (Berger EA, Del Castillo CM:) A novel protein for prevention and treatment of HIV infection. WO-00055207 (2000).
44. Fuji Photo Film Co LTD (Ono M, Wada Y, Wu Y, Chen LB, Kitaguchi H, Jimbo Y, Nemori R, Gillies S, Lo K-M:) Use of a naphthalenesulfonic acid compound for inhibiting retroviral infection. WO-09533459 (1995).
45. Progenics Pharmaceuticals Inc (Litwin VM; Allaway, GP; Maddon, PJ:) Antibodies capable of inhibiting HIV-1 infection, accessory molecules recognized by them, and their use in drug design. WO-09726009 (1997).